6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed Jul 21, 2026 · 14d ago · Accession 0001213900-26-079822
Plain English
Alpha Tau Medical Ltd. reported positive data from a study of Alpha DaRT® in combination with Pembrolizumab for head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival. This result surpassed the study's pre-specified threshold for success.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- Jul 21, 2026
- Report date
- Jul 21, 2026
- Document
- ea0298609-6k_alpha.htm
- Size
- 37 KB